Peter Van Dam professor

Publications Peter Van Dam

WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors : type 1 T-lymphocyte responses are associated with clinical outcome

Source
Journal of hematology and oncology - ISSN 1756-8722-18:1 (2025) p. 1-6
Author(s)

Response to letter entitled: Re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - a population-based study in Belgium

Source
European journal of cancer - ISSN 0959-8049-215 (2025) p. 1-3
Author(s)
    Roos Leroy, Jolyce Bourgeois, Jean-Luc Canon, Birgit Carly, Evandro de Azambuja, Peter André Van Dam, Liv Veldeman

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Source
Gynecologic oncology - ISSN 0090-8258-191 (2024) p. 275-286
Author(s)
    Emiel A. De Jaeghere, Hannelore Hamerlinck, Sandra Tuyaerts, Lien Lippens, An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter André Van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen Van de Vijver, Frederic Amant, Katrien Vandecasteel, Bruno Verhasselt, Hannelore G. Denys

An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)

Source
International journal of gynecological cancer - ISSN 1048-891X-34:8 (2024) p. 1217-1224
Author(s)
    Rita Trozzi, Sandra Tuyaerts, Daniela Annibali, Alejandro Herreros Pomares, Lotte Boog, Peter André Van Dam, Karin Leunen, Christophe Deroose, Hans Trum, Frédéric Amant